WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced the launch of Rezlidhia or olutasidenib capsules in the U.S. for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation. The approval from FDA was received on December 1.
REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
The company said the recommended dosage of REZLIDHIA is 150 mg taken orally twice daily.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX